OBJECTIVE: This study tested the hypothesis that preterm infants who had a blood gas derangement on at least 2 of the first 3 postnatal days are at increased risk for more severe retinopathy of prematurity (ROP). METHOD: 1,042 infants born before 28 weeks' gestational age (GA) were included. An infant was considered to be exposed if his/her blood gas measure was in the highest or lowest quartile for GA on at least 2 of the first 3 postnatal days. RESULTS: Multivariable models adjusting for confounders indicate that exposure to a PCO(2) in the highest quartile predicts ROP (stage 3, 4 or 5: OR = 1.6, 95% CI = 1.1-2.3); zone 1: 2.0, 1.1-3.6; prethreshold/threshold: 1.9, 1.2-3.0; plus disease: 1.8, 1.1-2.9). Estimates are similar for a low pH for zone 1 (2.1, 1.2-3.8), prethreshold/threshold (1.8, 1.1-2.8), but did not quite achieve statistical significance for ROP stage 3, 4, or 5 (1.4, 0.9-2.0) and plus disease (1.5, 0.9-2.4). A PaO(2) in the highest quartile for GA on at least 2 of the first 3 postnatal days was associated with a doubling of the risk of ROP in zone 1 (2.5, 1.4-4.4) and of prethreshold/threshold disease (2.1, 1.4-3.3), a 70% risk increase for plus disease (1.7, 1.04-2.8), while a 40% risk increase for ROP stage 3 or higher did not achieve statistical significance (1.4, 0.96-2.0). CONCLUSION: Infants exposed to high PCO(2), low pH and high PaO(2) appear to be at increased risk of more severe ROP.
OBJECTIVE: This study tested the hypothesis that preterm infants who had a blood gas derangement on at least 2 of the first 3 postnatal days are at increased risk for more severe retinopathy of prematurity (ROP). METHOD: 1,042 infants born before 28 weeks' gestational age (GA) were included. An infant was considered to be exposed if his/her blood gas measure was in the highest or lowest quartile for GA on at least 2 of the first 3 postnatal days. RESULTS: Multivariable models adjusting for confounders indicate that exposure to a PCO(2) in the highest quartile predicts ROP (stage 3, 4 or 5: OR = 1.6, 95% CI = 1.1-2.3); zone 1: 2.0, 1.1-3.6; prethreshold/threshold: 1.9, 1.2-3.0; plus disease: 1.8, 1.1-2.9). Estimates are similar for a low pH for zone 1 (2.1, 1.2-3.8), prethreshold/threshold (1.8, 1.1-2.8), but did not quite achieve statistical significance for ROP stage 3, 4, or 5 (1.4, 0.9-2.0) and plus disease (1.5, 0.9-2.4). A PaO(2) in the highest quartile for GA on at least 2 of the first 3 postnatal days was associated with a doubling of the risk of ROP in zone 1 (2.5, 1.4-4.4) and of prethreshold/threshold disease (2.1, 1.4-3.3), a 70% risk increase for plus disease (1.7, 1.04-2.8), while a 40% risk increase for ROP stage 3 or higher did not achieve statistical significance (1.4, 0.96-2.0). CONCLUSION:Infants exposed to high PCO(2), low pH and high PaO(2) appear to be at increased risk of more severe ROP.
Authors: Ann Hellström; Eva Engström; Anna-Lena Hård; Kerstin Albertsson-Wikland; Björn Carlsson; Aimon Niklasson; Chatarina Löfqvist; Elisabeth Svensson; Sture Holm; Uwe Ewald; Gerd Holmström; Lois E H Smith Journal: Pediatrics Date: 2003-11 Impact factor: 7.124
Authors: Jonathan L Hecht; Elizabeth N Allred; Harvey J Kliman; Eduardo Zambrano; Barbara J Doss; Aliya Husain; Solveig M V Pflueger; Chung-Ho Chang; Chad A Livasy; Drucilla Roberts; Ina Bhan; Dennis W Ross; Patricia Kaman Senagore; Alan Leviton Journal: Pathology Date: 2008-06 Impact factor: 5.306
Authors: Andrew B Onderdonk; Jonathan L Hecht; Thomas F McElrath; Mary L Delaney; Elizabeth N Allred; Alan Leviton Journal: Am J Obstet Gynecol Date: 2008-03-07 Impact factor: 8.661
Authors: T F McElrath; J L Hecht; O Dammann; K Boggess; A Onderdonk; G Markenson; M Harper; E Delpapa; E N Allred; A Leviton Journal: Am J Epidemiol Date: 2008-08-27 Impact factor: 4.897
Authors: M Chatterjee; X Ge; Y Kostov; P Luu; L Tolosa; H Woo; R Viscardi; S Falk; R Potts; G Rao Journal: Physiol Meas Date: 2015-04-02 Impact factor: 2.833
Authors: Minghua L Chen; Elizabeth N Allred; Jonathan L Hecht; Andrew Onderdonk; Deborah VanderVeen; David K Wallace; Alan Leviton; Olaf Dammann Journal: Invest Ophthalmol Vis Sci Date: 2011-09-01 Impact factor: 4.799
Authors: Elizabeth N Allred; Antonio Capone; Anthony Fraioli; Olaf Dammann; Patrick Droste; Jay Duker; Robert Gise; Karl Kuban; Alan Leviton; T Michael O'Shea; Nigel Paneth; Robert Petersen; Michael Trese; Kathleen Stoessel; Deborah Vanderveen; David K Wallace; Grey Weaver Journal: J AAPOS Date: 2014-06 Impact factor: 1.220
Authors: Juliann M Di Fiore; Farhad Kaffashi; Kenneth Loparo; Abdus Sattar; Mark Schluchter; Ryan Foglyano; Richard J Martin; Christopher G Wilson Journal: Pediatr Res Date: 2012-10-04 Impact factor: 3.756
Authors: Anuradha Phadke; Michael E Msall; Patrick Droste; Elizabeth N Allred; Thomas Michael O'Shea; Karl Kuban; Olaf Dammann; Alan Leviton Journal: Pediatr Neurol Date: 2014-03-15 Impact factor: 3.372
Authors: Angelo Polito; Simone Piga; Paola E Cogo; Carlo Corchia; Virgilio Carnielli; Monica Da Frè; Domenico Di Lallo; Isabella Favia; Luigi Gagliardi; Francesco Macagno; Silvana Miniaci; Marina Cuttini Journal: Intensive Care Med Date: 2013-03-28 Impact factor: 17.440
Authors: Yanchao Jiang; Haibo Wang; David Culp; Zhihong Yang; Lori Fotheringham; John Flannery; Scott Hammond; Tal Kafri; M Elizabeth Hartnett Journal: Invest Ophthalmol Vis Sci Date: 2014-02-10 Impact factor: 4.799